American Vanguard (AVD) 10-Q 2 Nov 16 2016 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2016	Oct. 25, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q3
Trading Symbol	AVD
Entity Registrant Name	AMERICAN VANGUARD CORP
Entity Central Index Key	5,981
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		29,360,039

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Income Statement [Abstract]
Net sales	$ 82,447	$ 72,486	$ 224,645	$ 205,574
Cost of sales	49,461	41,053	132,761	124,370
Gross profit	32,986	31,433	91,884	81,204
Operating expenses	28,255	26,059	77,429	74,325
Operating income	4,731	5,374	14,455	6,879
Interest expense	301	638	1,304	1,941
Income before provision for income taxes and loss on equity investment	4,430	4,736	13,151	4,938
Income tax expense	1,409	1,643	3,672	958
Income before loss on equity investment	3,021	3,093	9,479	3,980
Net loss from equity investment	(180)	(389)	(309)	(580)
Net income	2,841	2,704	9,170	3,400
Add back net loss (income) attributable to non-controlling interest	36	68	(253)	204
Net income attributable to American Vanguard	$ 2,877	$ 2,772	$ 8,917	$ 3,604
Earnings per common share—basic	$ 0.10	$ 0.10	$ 0.31	$ 0.13
Earnings per common share—assuming dilution	$ 0.10	$ 0.09	$ 0.30	$ 0.12
Weighted average shares outstanding—basic	28,957	28,753	28,886	28,653
Weighted average shares outstanding—assuming dilution	29,496	29,289	29,385	29,208

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 6,594	$ 5,524
Receivables:
Trade, net of allowance for doubtful accounts of $159 and $423, respectively	91,091	72,835
Other	3,500	2,554
Total receivables	94,591	75,389
Inventories	141,678	136,477
Prepaid expenses	12,270	11,172
Income taxes receivable		168
Deferred income tax assets	8,101	8,101
Total current assets	263,234	236,831
Property, plant and equipment, net	47,760	47,972
Intangible assets, net of applicable amortization	123,420	129,160
Other assets	28,695	29,576
Total assets	463,109	443,539
Current liabilities:
Current installments of other notes payable	0	55
Current installments of other liabilities	74	514
Accounts payable	23,268	15,343
Deferred revenue	41	8,888
Accrued program costs	74,907	44,371
Accrued expenses and other payables	10,209	7,111
Income taxes payable	1,269
Total current liabilities	109,768	76,282
Long-term debt and other notes payable, excluding current installments	44,488	68,321
Other liabilities, excluding current installments	3,036	3,054
Deferred income tax liabilities	27,556	27,556
Total liabilities	184,848	175,213
Commitments and contingent liabilities
Stockholders' Equity:
Preferred stock, $.10 par value per share; authorized 400,000 shares; none issued
Common stock, $.10 par value per share; authorized 40,000,000 shares; issued 31,807,223 shares at September 30, 2016 and 31,638,225 shares at December 31, 2015	3,182	3,164
Additional paid-in capital	70,458	68,534
Accumulated other comprehensive loss	(4,429)	(3,541)
Retained earnings	217,135	208,507
Total stockholders' equity including treasury stock	286,346	276,664
Less treasury stock, at cost, 2,450,634 shares at September 30, 2016 and December 31, 2015	(8,269)	(8,269)
American Vanguard Corporation stockholders’ equity	278,077	268,395
Non-controlling interest	184	(69)
Total stockholders’ equity	278,261	268,326
Total liabilities and stockholders' equity	$ 463,109	$ 443,539

CONDENSED CONSOLIDATED BALANCE4

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Statement Of Financial Position [Abstract]
Allowance for doubtful accounts	$ 159	$ 423
Preferred stock, par value per share	$ 0.10	$ 0.10
Preferred stock, shares authorized	400,000	400,000
Preferred stock, shares issued	0	0
Common stock, par value per share	$ 0.10	$ 0.10
Common stock, shares authorized	40,000,000	40,000,000
Common stock, shares issued	31,807,223	31,638,225
Treasury stock, shares	2,450,634	2,450,634

CONDENSED CONSOLIDATED STATEME5

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income/(loss)	Retained Earnings	Treasury Stock	AVD Total	Non- Controlling Interest
Balance at Dec. 31, 2014				$ (1,970)
Foreign currency translation adjustment, net				(248)
Balance at Mar. 31, 2015				(2,218)
Balance at Dec. 31, 2014				(1,970)
Foreign currency translation adjustment, net	$ (1,468)
Net income (loss)	3,400
Balance at Sep. 30, 2015				(3,438)
Balance at Mar. 31, 2015				(2,218)
Foreign currency translation adjustment, net				(323)
Balance at Jun. 30, 2015				(2,541)
Foreign currency translation adjustment, net	(897)			(897)
Net income (loss)	$ 2,704
Balance at Sep. 30, 2015				(3,438)
Balance (in shares) at Dec. 31, 2015	31,638,225	31,638,225				2,450,634
Balance at Dec. 31, 2015	$ 268,326	$ 3,164	$ 68,534	(3,541)	$ 208,507	$ (8,269)	$ 268,395	$ (69)
Stocks issued under ESPP (in shares)		19,627
Stocks issued under ESPP	271	$ 2	269				271
Foreign currency translation adjustment, net	85			85			85
Stock based compensation	456		456				456
Stock options exercised and grants, vesting and forfeited restricted stock units	(586)	$ (6)	(580)				(586)
Stock options exercised and grants, vesting and forfeited restricted stock units, Shares		(61,550)
Excess tax benefits from share based payment arrangements	35		35				35
Net income (loss)	2,947				2,794		2,794	153
Balance (in shares) at Mar. 31, 2016		31,596,302				2,450,634
Balance at Mar. 31, 2016	$ 271,534	$ 3,160	68,714	(3,456)	211,301	$ (8,269)	271,450	84
Balance (in shares) at Dec. 31, 2015	31,638,225	31,638,225				2,450,634
Balance at Dec. 31, 2015	$ 268,326	$ 3,164	68,534	(3,541)	208,507	$ (8,269)	268,395	(69)
Foreign currency translation adjustment, net	(888)
Net income (loss)	$ 9,170
Balance (in shares) at Sep. 30, 2016	31,807,223	31,807,223				2,450,634
Balance at Sep. 30, 2016	$ 278,261	$ 3,182	70,458	(4,429)	217,135	$ (8,269)	278,077	184
Balance (in shares) at Mar. 31, 2016		31,596,302				2,450,634
Balance at Mar. 31, 2016	271,534	$ 3,160	68,714	(3,456)	211,301	$ (8,269)	271,450	84
Cash dividends on common stock ($0.01 per share)	(289)				(289)		(289)
Foreign currency translation adjustment, net	(537)			(537)			(537)
Stock based compensation	612		612				612
Stock options exercised and grants, vesting and forfeited restricted stock units	120	$ 20	100				120
Stock options exercised and grants, vesting and forfeited restricted stock units, Shares		192,342
Excess tax benefits from share based payment arrangements	12		12				12
Net income (loss)	3,382				3,246		3,246	136
Balance (in shares) at Jun. 30, 2016		31,788,644				2,450,634
Balance at Jun. 30, 2016	274,834	$ 3,180	69,438	(3,993)	214,258	$ (8,269)	274,614	220
Stocks issued under ESPP (in shares)		23,103
Stocks issued under ESPP	291	$ 2	289				291
Foreign currency translation adjustment, net	(436)			(436)			(436)
Stock based compensation	588		588				588
Stock options exercised and grants, vesting and forfeited restricted stock units	108		108				108
Stock options exercised and grants, vesting and forfeited restricted stock units, Shares		(4,524)
Excess tax benefits from share based payment arrangements	35		35				35
Net income (loss)	$ 2,841				2,877		2,877	(36)
Balance (in shares) at Sep. 30, 2016	31,807,223	31,807,223				2,450,634
Balance at Sep. 30, 2016	$ 278,261	$ 3,182	$ 70,458	$ (4,429)	$ 217,135	$ (8,269)	$ 278,077	$ 184

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)	3 Months Ended
	Jun. 30, 2016$ / shares
Statement Of Stockholders Equity [Abstract]
Cash dividends on common stock, per share	$ 0.01

CONDENSED CONSOLIDATED STATEME7

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Statement Of Income And Comprehensive Income [Abstract]
Net income attributable to American Vanguard	$ 2,877	$ 2,772	$ 8,917	$ 3,604
Foreign currency translation adjustment	(436)	(897)	(888)	(1,468)
Comprehensive income	$ 2,441	$ 1,875	$ 8,029	$ 2,136

CONDENSED CONSOLIDATED STATEME8

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash flows from operating activities:
Net income	$ 9,170	$ 3,400
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization of fixed and intangible assets	12,367	12,190
Amortization of other long term assets	3,935	3,992
Amortization of discounted liabilities	28	118
Stock-based compensation	1,656	2,943
Tax benefit from exercise of stock options	(82)	(8)
Operating loss from equity method investment	309	580
Changes in assets and liabilities associated with operations:
Increase in net receivables	(19,202)	(6,172)
(Increase) decrease in inventories	(5,201)	4,135
(Increase) decrease in prepaid expenses and other assets	(1,011)	1,143
Decrease in income tax receivable/payable, net	1,519	4,739
Increase in accounts payable	7,925	3,010
Decrease in deferred revenue	(8,847)	(860)
Increase in program payables	30,536	20,982
Increase in other payables and accrued expenses	3,098	1,615
Net cash provided by operating activities	36,200	51,807
Cash flows from investing activities:
Capital expenditures	(6,122)	(5,196)
Investments	(3,283)	(125)
Acquisitions of product lines and other intangible assets	(224)	(36,435)
Net cash used in investing activities	(9,629)	(41,756)
Cash flows from financing activities:
Net payments under line of credit agreement	(24,000)	(16,120)
Increase in other notes payable		10,000
Payments on other long-term liabilities	(541)	(1,252)
Tax benefit from exercise of stock options	82	8
Payment of cash dividends	(289)	(1,141)
Net proceeds from the issuance of common stock (sale of stock under ESPP and exercise of stock options)	204	254
Net cash used in financing activities	(24,544)	(8,251)
Net increase in cash and cash equivalents	2,027	1,800
Cash and cash equivalents at beginning of period	5,524	4,885
Effect of exchange rate changes on cash and cash equivalents	(957)	(1,256)
Cash and cash equivalents at end of period	$ 6,594	$ 5,429

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	1. The accompanying unaudited condensed consolidated financial statements of American Vanguard Corporation and Subsidiaries (“AVD” or “Company”) have been prepared in accordance with generally accepted accounting principles in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and nine months ended September 30, 2016 are not necessarily indicative of the results that may be expected for the year ending December 31, 2016. For further information, refer to the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015.

Property, Plant and Equipment

Property, Plant and Equipment	9 Months Ended
	Sep. 30, 2016
Property Plant And Equipment [Abstract]
Property, Plant and Equipment	2. Property, plant and equipment at September 30, 2016 and December 31, 2015 consists of the following: September 30, 2016 December 31, 2015 Land $ 2,458 $ 2,458 Buildings and improvements 15,067 14,726 Machinery and equipment 117,140 113,506 Office furniture, fixtures and equipment 4,857 4,997 Automotive equipment 383 491 Construction in progress 5,398 3,413 145,303 139,591 Less accumulated depreciation (97,543 ) (91,619 ) $ 47,760 $ 47,972 For the three months and nine months periods ended September 30, 2016, the Company recognized depreciation expense related to property, plant and equipment of $2,021 and $6,334, respectively. During the nine months ended September 30, 2016 and 2015, the Company eliminated from assets and accumulated depreciation $410 and $388 of fully depreciated assets, respectively. The Company recognized depreciation expense related to property, plant and equipment of $2,231 and $6,762 for the three months and nine months periods ended September 30, 2015, respectively. Substantially all of the Company’s assets are pledged as collateral with its banks.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2016
Inventory Disclosure [Abstract]
Inventories	3. Inventories are stated at the lower of cost or market. Cost is determined using the first-in, first-out method. The components of inventories consist of the following: September 30, 2016 December 31, 2015 Finished products $ 123,311 $ 120,456 Raw materials 18,367 16,021 $ 141,678 $ 136,477

Segment Reporting

Segment Reporting	9 Months Ended
	Sep. 30, 2016
Segment Reporting [Abstract]
Segment Reporting	4. Based on similar economic and operational characteristics, the Company’s business is aggregated into one reportable segment. Selective enterprise information is as follows: Three Months Ended September 30 Nine Months Ended September 30 2016 2015 2016 2015 Net sales: Insecticides $ 25,478 $ 23,539 $ 89,496 $ 85,484 Herbicides/soil fumigants/fungicides 34,242 32,682 80,009 71,973 Other, including plant growth regulators 13,328 7,420 23,148 23,497 Crop 73,048 63,641 192,653 180,954 Non-crop 9,399 8,845 31,992 24,620 Total net sales $ 82,447 $ 72,486 $ 224,645 $ 205,574 Net sales: US $ 60,033 $ 53,167 $ 161,661 $ 146,231 International 22,414 19,319 62,984 59,343 Total net sales $ 82,447 $ 72,486 $ 224,645 $ 205,574

Accrued Program Costs

Accrued Program Costs	9 Months Ended
	Sep. 30, 2016
Payables And Accruals [Abstract]
Accrued Program Costs	5. Accrued Program Costs

Cash Dividend

Cash Dividend	9 Months Ended
	Sep. 30, 2016
Cash Dividends [Abstract]
Cash Dividend	6. The Company has declared and paid the following cash dividends in the period covered by this Form 10-Q: Declaration Date Record Date Distribution Date Dividend Per Share Total Paid June 13, 2016 June 30, 2016 July 12, 2016 $ 0.01 $ 289 March 16, 2015 April 3, 2015 April 17, 2015 $ 0.02 $ 572 December 11, 2014 December 26, 2014 January 9, 2015 $ 0.02 $ 569

Earnings Per Share

Earnings Per Share	9 Months Ended
	Sep. 30, 2016
Earnings Per Share [Abstract]
Earnings Per Share	7. ASC 260 Earnings Per Share (“EPS”) The components of basic and diluted earnings per share were as follows (in thousands): Three Months Ended September 30 Nine Months Ended September 30 2016 2015 2016 2015 Numerator: Net income attributable to AVD $ 2,877 $ 2,772 $ 8,917 $ 3,604 Denominator: Weighted average shares outstanding-basic 28,957 28,753 28,886 28,653 Dilutive effect of stock options and grants 539 536 499 555 29,496 29,289 29,385 29,208 For the three months and nine months ended September 30, 2016 and 2015, no stock options were excluded from the computation of diluted earnings per share.

Indebtedness

Indebtedness	9 Months Ended
	Sep. 30, 2016
Debt Disclosure [Abstract]
Indebtedness	8. The Company has a revolving line of credit and two other notes payable that together constitute the short-term and long-term loan balances shown in the condensed consolidated balance sheets at September 30, 2016 and December 31, 2015. During 2015 the Company adopted ASU 2015-03, Interest – Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs Indebtedness September 30, 2016 December 31, 2015 $000’s Long- term Short- term Total Long- term Short- term Total Revolving line of credit $ 45,000 $ — $ 45,000 $ 69,000 $ — $ 69,000 Deferred loan fees (512 ) — (512 ) (679 ) — (679 ) Notes payable — — — — 55 55 Total indebtedness $ 44,488 $ — $ 44,488 $ 68,321 $ 55 $ 68,376 AMVAC Chemical Corporation (“AMVAC”), the Company’s principal operating subsidiary, as borrower, and affiliates (including the Company), as guarantors and/or borrowers, are parties to a credit agreement dated as of July 11, 2014 (the “Credit Agreement”) with a group of commercial lenders led by Bank of the West (AMVAC’s primary bank) as agent, swing line lender and Letter of Credit (“LC”) issuer. The Credit Agreement is a senior secured lending facility with a five year term and consisting of a revolving line of credit of $200 million and an accordion feature for up to $100 million. The Credit Agreement includes both AMVAC CV (“AMVAC CV”) and AMVAC Netherlands BV (“AMVAC BV”) as borrowers. Under the Credit Agreement, revolving loans bear interest at a variable rate based, at borrower’s election with proper notice, on either (i) LIBOR plus the “Applicable Rate” which is based upon the Consolidated Funded Debt Ratio (“Eurocurrency Rate Loan”) or (ii) the greater of (x) the Prime Rate, (y) the Federal Funds Rate plus 0.5%, and (z) the Daily One-Month LIBOR Rate plus 1.00%, plus, in the case of (x), (y) or (z) the Applicable Rate (“Alternate Base Rate Loan”). Interest payments for Eurocurrency Rate Loans are payable on the last day of each interest period (either one, two, three or six months, as selected by the borrower) and the maturity date, while interest payments for Alternate Base Rate Loans are payable on the last business day of each month and the maturity date. The senior secured revolving line of credit matures on June 17, 2018. Under the Credit Agreement, the Company has three key covenants (with which it was in compliance throughout the nine months ended September 30, 2016). The covenants are as follows: (1) the Company must maintain its borrowings below a certain consolidated funded debt ratio, (2) the Company has a limitation on its annual spending on the acquisition of fixed asset capital additions, and (3) the Company must maintain a certain consolidated fixed charge coverage ratio. On April 14, 2015, AMVAC, as borrower, and affiliates (including the Company), as guarantors and/or borrowers, entered into an amendment to the Credit Agreement under which, the Consolidated Funded Debt Ratio was increased for the second, third and fourth quarters of 2015 (to 3.5-to-1 from 3.25-to-1) and a fixed charge covenant, requiring, in effect, that the ratio of consolidated current assets to consolidated current liabilities exceed 1.2-to-1 for the duration of the term of the credit facility, was added. At September 30, 2016, based on its performance against the most restrictive covenants listed above, the Company had the capacity to increase its borrowings by up to $95,985, according to the terms of the Credit Agreement. This compares to an available borrowing capacity of $40,189 as of September 30, 2015. The level of borrowing capacity was driven by three factors: (1) our financial performance, as measured in Earnings Before Interest, Tax, Depreciation and Amortization (“EBITDA”) for the trailing twelve month period, has improved, (2) the level of borrowings during the third quarter of 2015 was higher than normal due to the then recent completion of two product line acquisitions, and (3) the leverage covenant (being the number of times EBITDA the Company may borrow under its credit facility agreement) was lower when compared with the earlier period.

Reclassification

Reclassification	9 Months Ended
	Sep. 30, 2016
Text Block [Abstract]
Reclassification	9. Reclassification—Certain items have been reclassified in the prior period condensed consolidated financial statements to conform with the September 30, 2016 presentation.

Comprehensive income

Comprehensive income	9 Months Ended
	Sep. 30, 2016
Equity [Abstract]
Comprehensive income	10. Total comprehensive income includes, in addition to net income, changes in equity that are excluded from the condensed consolidated statements of operations and are recorded directly into a separate section of stockholders’ equity on the condensed consolidated balance sheets. For the three month and nine month periods ended September 30, 2016 and 2015, total comprehensive income consisted of net income attributable to American Vanguard and foreign currency translation adjustments.

Stock Based Compensation

Stock Based Compensation	9 Months Ended
	Sep. 30, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Based Compensation	11. Stock Based Compensation—The Company accounts for stock-based awards to employees and directors in accordance with FASB ASC 718, “ Share-Based Payment, The below tables illustrate the Company’s stock based compensation, unamortized stock-based compensation, and remaining weighted average period for the three months and nine months ended September 30, 2016 and 2015. Stock-Based Compensation for the Three months ended Stock-Based Compensation for the Nine months ended Unamortized Stock-Based Compensation Remaining Weighted Average Period (years) September 30, 2016 Incentive Stock Options $ 71 $ 252 $ 497 1.2 Restricted Stock 406 1,100 2,545 1.8 Performance Based Restricted Stock 100 240 857 1.4 Performance Based Options 11 64 173 1.2 Total $ 588 $ 1,656 $ 4,072 September 30, 2015 Incentive Stock Options $ 94 $ 325 $ 1,009 2.3 Restricted Stock 334 2,296 2,751 1.5 Performance Based Restricted Stock 18 222 686 1.8 Performance Based Options 12 100 373 2.2 Total $ 458 $ 2,943 $ 4,819 Stock Options—During the nine months ended September 30, 2016, the Company did not grant any employees options to acquire shares of common stock. Option activity within each plan is as follows: Incentive Stock Option Plans Weighted Average Price Per Share Exercisable Weighted Average Price Per Share Balance outstanding, December 31, 2015 626,845 $ 9.25 $ 7.73 Options exercised (25,500 ) 7.50 Options forfeited (9,813 ) 11.49 Balance outstanding, March 31, 2016 591,532 $ 9.29 $ 7.84 Options exercised (12,900 ) 7.50 Options forfeited (5,000 ) 11.49 Balance outstanding, June 30, 2016 573,632 $ 9.31 $ 7.85 Options exercised (15,500 ) 7.50 Options forfeited (11,118 ) 11.49 Balance outstanding, September 30, 2016 547,014 $ 9.31 $ 7.87 Information relating to stock options at September 30, 2016 summarized by exercise price is as follows: Outstanding Weighted Average Exercisable Weighted Average Exercise Price Per Share Shares Remaining Life (Months) Exercise Price Shares Exercise Price Incentive Stock Option Plan: $7.50 303,350 50 $ 7.50 303,350 $ 7.50 $11.32—$11.49 243,664 95 $ 11.57 25,507 $ 12.28 547,014 $ 9.31 328,857 $ 7.87 The weighted average exercise prices for options granted and exercisable and the weighted average remaining contractual life for options outstanding as of September 30, 2016 was as follows: Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Months) Intrinsic Value (thousands) As of September 30, 2016: Incentive Stock Option Plans: Outstanding 547,014 $ 9.31 70 $ 3,690 Expected to Vest 540,064 $ 9.29 70 $ 3,658 Exercisable 328,857 $ 7.87 51 $ 2,693 During the three months ended September 30, 2016 and 2015, the Company recognized stock-based compensation related to stock options of $71 and $94, respectively. During the nine months ended September 30, 2016 and 2015, the Company recognized stock-based compensation related to stock options of $252 and $325, respectively. As of September 30, 2016, the Company had approximately $497 of unamortized stock-based compensation related to unvested stock options outstanding. This amount will be recognized over the weighted-average period of 1.2 years. This projected expense will change if any stock options are granted or cancelled prior to the respective reporting periods or if there are any changes required to be made for estimated forfeitures. Restricted Shares — Nine Months Ended September 30, 2016 Nine Months Ended September 30, 2015 Number of Shares Weighted Average Grant Date Fair Value Number of Shares Weighted Average Grant Date Fair Value Nonvested shares at January 1 st 362,841 $ 20.43 560,842 $ 21.44 Granted — — 30,000 11.42 Vested (127,274 ) 31.29 (192,266 ) 20.47 Forfeited (16,008 ) 23.67 (422 ) 14.92 Nonvested shares at March 31 st 219,559 $ 14.59 398,154 $ 21.17 Granted 140,541 15.08 21,005 14.28 Vested (22,639 ) 15.63 (28,505 ) 13.53 Forfeited (6,457 ) 14.98 (1,201 ) 14.92 Nonvested shares at June 30 th 331,004 $ 14.72 389,453 $ 21.37 Granted 1,668 16.75 13,196 12.88 Vested (2,566 ) 19.18 (19,000 ) 27.93 Forfeited (12,822 ) 14.98 (26,723 ) 22.64 Nonvested shares at September 30 th 317,284 $ 14.69 356,926 $ 20.62 Restricted shares — During the nine months ended September 30, 2016, the Company granted a total of 142,209 shares of common stock. Of these, 21,139 shares vest immediately and the remaining 121,070 will cliff vest after three years of service. The shares granted in 2016 were average fair valued at $15.10 per share. The fair value was determined by using the publicly traded share price as of the date of grant. The Company is recognizing as expense the value of restricted shares over the required service period. During the nine months ended September 30, 2015, the Company granted a total of 64,201 shares of common stock. Of these, 21,005 shares vest immediately, 7,500 shares will vest after 90 days from date of grant, 3,196 shares will vest one-third each year on the anniversaries of the employee’s employment date and the balance will cliff vest after three years of service. The shares granted in 2015 were average fair valued at $12.66 per share. The fair value was determined by using the publicly traded share price as of the date of grant. The Company is recognizing as expense the value of restricted shares over the required service period. During the three months ended September 30, 2016 and 2015, the Company recognized stock-based compensation related to restricted shares of $406 and $334, respectively. During the nine months ended September 30, 2016 and 2015, the Company recognized stock-based compensation related to restricted shares of $1,100 and $2,296, respectively. As of September 30, 2016, the Company had approximately $2,545 of unamortized stock-based compensation related to unvested restricted shares. This amount will be recognized over the weighted-average period of 1.8 years. This projected expense will change if any restricted shares are granted or cancelled prior to the respective reporting periods or if there are any changes required to be made for estimated forfeitures. Performance Based Restricted Shares — Nine Months Ended September 30, 2016 Nine Months Ended September 30, 2015 Number of Shares Weighted Average Grant Date Fair Value Number of Shares Weighted Average Grant Date Fair Value Nonvested shares at January 1 st 104,403 $ 17.05 103,907 $ 17.77 Granted — — 7,500 10.96 Forfeited (9,395 ) 17.65 — — Nonvested shares at March 31 st 95,008 $ 16.99 111,407 $ 17.31 Granted 52,170 14.39 — — Forfeited (19,612 ) 28.25 — — Nonvested shares at June 30 th 127,566 $ 14.20 111,407 $ 17.31 Granted — — 3,196 12.37 Forfeited (8,544 ) 14.39 (10,200 ) 18.43 Nonvested shares at September 30 th 119,022 $ 14.18 104,403 $ 17.05 Performance Based Restricted Shares — During the nine months ended September 30, 2016, the Company granted a total of 52,170 performance based shares that will cliff vest on January 6, 2019, provided that the recipients are individually continuously employed by the Company during the vesting period. These shares have a measurement period commencing January 1, 2016 and ending December 31, 2018. Eighty percent of these performance based shares are based upon financial performance of the Company, specifically, an earnings before income tax (“EBIT”) goal weighted at 50% and a net sales goal weighted at 30%. The remaining 20% of performance based shares are based upon AVD stock price appreciation over the same performance measurement period. The EBIT and net sales goals measure the relative growth of the Company’s EBIT and net sales for the performance measurement period, as compared to the median growth of EBIT and net sales for an identified peer group. The stockholder return goal measures the relative growth of the fair market value of the Company’s stock price over the performance measurement period, as compared to that of the Russell 2000 Index and the median fair market value of the common stock of the comparator companies, identified in the Company’s 2015 Proxy Statement. All parts of these awards vest in three years, but are subject to reduction to a minimum (or even zero) for meeting less than the targeted performance and to increase to a maximum of 200% for meeting in excess of the targeted performance. During the nine months ended September 30, 2015, the Company granted a total of 10,696 performance based shares. Of these, 7,500 shares will cliff vest on January 5, 2018 with a measurement period commencing January 1, 2015 and ending December 31, 2017 and 3,196 shares will cliff vest on August 1, 2018 with a measurement period commencing July 1, 2015 and ending June 30, 2018, provided that the recipient is continuously employed by the Company during the vesting period. Eighty percent of these performance based shares are based upon financial performance of the Company, specifically, an earnings before income tax (“EBIT”) goal weighted at 50% and a net sales goal weighted at 30%. The remaining 20% of performance based shares are based upon AVD stock price appreciation over the same performance measurement period. The EBIT and net sales goals measure the relative growth of the Company’s EBIT and net sales for the performance measurement period, as compared to the median growth of EBIT and net sales for an identified peer group. The stockholder return goal measures the relative growth of the fair market value of the Company’s stock price over the performance measurement period, as compared to that of the Russell 2000 Index and the median fair market value of the common stock of the comparator companies, identified in the Company’s 2014 Proxy Statement. All parts of these awards vest in three years, but are subject to reduction to a minimum (or even zero) for meeting less than the targeted performance and to increase to a maximum of 200% for meeting in excess of the targeted performance. As of September 30, 2016, performance based shares related to net income and net sales have an average fair value of $15.08 per share. The fair value was determined by using the publicly traded share price as of the date of grant. The performance based shares related to the Company’s stock price have an average fair value of $11.63 per share. The fair value was determined by using the Monte Carlo valuation method. For awards with performance conditions, the Company recognizes share-based compensation cost on a straight-line basis for each performance criteria over the implied service period. During the three months ended September 30, 2016 and 2015, the Company recognized stock-based compensation related to performance based shares of $100 and $18, respectively. During the nine months ended September 30, 2016 and 2015, the Company recognized stock-based compensation related to performance based shares of $240 and $222, respectively. As of September 30, 2016, the Company had approximately $857 of unamortized stock-based compensation related to unvested performance based shares. This amount will be recognized over the weighted-average period of 1.4 years. This projected expense will change if any performance based shares are granted or cancelled prior to the respective reporting periods or if there are any changes required to be made for estimated forfeitures. Performance Based Stock Options—During the nine months ended September 30, 2016 and 2015, the Company did not grant any employees performance incentive stock options to acquire shares of common stock. Performance based stock option activity is as follows: Incentive Stock Option Plans Weighted Average Price Per Share Exercisable Weighted Average Price Per Share Balance outstanding, December 31, 2015 98,410 $ 11.49 $ — Options forfeited (8,946 ) 11.49 Balance outstanding, March 31, 2016 89,464 $ 11.49 $ — Balance outstanding, June 30, 2016 89,464 $ 11.49 Options forfeited (7,130 ) 11.49 Balance outstanding, September 30, 2016 82,334 $ 11.49 $ — Information relating to outstanding performance incentive stock options at September 30, 2016 summarized by exercise price is as follows: Outstanding Weighted Average Exercisable Weighted Average Exercise Price Per Share Shares Remaining Life (Months) Exercise Price Shares Exercise Price Performance Incentive Stock Option Plan: $11.49 82,334 15 $ 11.49 — $ — 82,334 $ 11.49 — $ — The weighted average exercise prices for options granted and exercisable and the weighted average remaining contractual life for options outstanding as of September 30, 2016 are as follows: Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Months) Intrinsic Value (thousands) As of September 30, 2016: Incentive Stock Option Plans: Outstanding 82,334 $ 11.49 15 $ 376 Expected to Vest 73,632 $ 11.49 15 $ 336 Exercisable — $ — — $ — During the three months ended September 30, 2016 and 2015, the Company recognized stock-based compensation related to performance stock options of $11 and $12, respectively. During the nine months ended September 30, 2016 and 2015, the Company recognized stock-based compensation related to performance stock options of $64 and $100, respectively. As of September 30, 2016, the Company had approximately $173 of unamortized stock-based compensation related to unvested performance incentive stock options outstanding. This amount will be recognized over the weighted-average period of 1.2 years. This projected expense will change if any performance incentive stock options are granted or cancelled prior to the respective reporting periods or if there are any changes required to be made for estimated forfeitures.

Legal Proceedings

Legal Proceedings	9 Months Ended
	Sep. 30, 2016
Commitments And Contingencies Disclosure [Abstract]
Legal Proceedings	12. Legal Proceedings—During the reporting period, there have been no material developments in the legal proceedings that were reported in the Company’s Form 10-K for the period ended December 31, 2015 other than as discussed below: DBCP Matters – Delaware Over the course of the past 30 years, AMVAC and/or the Company have been named or otherwise implicated in a number of lawsuits concerning injuries allegedly arising from either contamination of water supplies or personal exposure to 1, 2-dibromo-3-chloropropane (“DBCP ® Several cases involving 235 banana workers from Costa Rica, Ecuador and Panama had been separately filed in U.S. District Court in Delaware in 2012 and subsequently consolidated into one matter (the “Hendler-Delaware Case”). These matters involved the same claimants and claims that had been filed in U.S. District Court in Louisiana within the prior year (and which we refer to as the Hendler-Louisiana Cases). On August 21, 2012, the U.S. District Court in the Hendler-Delaware case granted defendants’ motion to dismiss the actions with prejudice, finding that the same claimants and claims had been pending in the Hendler-Louisiana cases where they had been first filed. In October 2012, the federal district court in Louisiana granted defendants’ motion for summary judgment and dismissed the Hendler-Louisiana Cases for plaintiffs’ failure to bring the action within the applicable statute of limitations. Plaintiffs appealed the dismissal of the Hendler-Louisiana cases and, on September 19, 2013, the Fifth Circuit Court of Appeal upheld the lower court’s decision, finding no reason to reverse the dismissal. On October 16, 2013, plaintiffs filed a notice of appeal in the Hendler-Delaware case. Oral argument was heard before the Third Circuit Court of Appeal on June 24, 2014 in connection with that appeal, and, on August 11, 2015, the Third Circuit upheld the lower court’s dismissal of the Hendler-Delaware case. However, plaintiffs petitioned for rehearing en banc, arguing that, despite the fact that the same plaintiffs had made the same claims before another court (namely, the Louisiana court in the Hendler-Louisiana Cases), because the Louisiana court had not decided the case on the merits (but, rather, on the basis of the statute of limitations), the Delaware trial court lacked the power to dismiss the Hendler-Delaware case with prejudice. On September 22, 2015, the Third Circuit vacated its previous ruling (to uphold the lower court dismissal) and reheard the matter en banc On September 2, 2016, the Third Circuit Court reversed the District Court decision, finding that it was not proper for the trial court to have dismissed these cases with prejudice even though the Louisiana courts had dismissed the same claims for expiration of the statute of limitations. In reaching its decision, the Third Circuit reasoned that no court had yet addressed the merits of the matter, that Delaware’s statute of limitations may differ from that of Louisiana, and that it would have been proper for the Delaware trial court to have dismissed the matter without prejudice (that is, with the right to amend and refile). Accordingly, the matter has been remanded to the U.S. District Court in Delaware. The Company believes the Hendler-Delaware case has no merit and, further, that a loss is neither probable nor reasonably estimable; accordingly, it has not recorded a loss contingency. Other Matters U.S. EPA RCRA/FIFRA Matter In the course of its investigation, the agency has also pointed out alleged anomalies relating to the Company’s confidential statements of formula relating to the use of certain inert materials in formulation. USEPA’s Region 5 has expressed its intention to bring an enforcement action relating to its overall findings. AMVAC believes that it has lawfully imported Thimet from Canada and Australia for the purpose of potentially refilling, reprocessing or properly disposing of them. Further, the Company believes that it has carried out its Thimet business in good faith, maintained a focus on product stewardship and, in the process, did not pose any increased risk of harm to human health or the environment. On October 11, 2016, the Company met with USEPA’s Office of Enforcement and Compliance (as well as with Regions 4 and 5) to clarify a path forward to ensure future compliance. However, the Company has not yet received a final position from USEPA with regard to past acts, and, at this stage, it is too early to tell whether a loss arising from either the OSC or SSURO is probable or reasonably estimable. Accordingly, the Company has not recorded a loss contingency on this matter. Galvan v. AMVAC Graciela Galvan v. AMVAC Chemical Corp. DeChene Farms

Recently Issued Accounting Guid

Recently Issued Accounting Guidance	9 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Recently Issued Accounting Guidance	13. Recently Issued Accounting Guidance—In August 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-15, Statement of Cash Flows (Topic 230) In March 2016, FASB issued ASU 2016-09, Compensation—Stock Compensation (Topic 718) In March 2016, FASB issued ASU 2016-07, Investments—Equity Method and Joint Ventures In February 2016, FASB issued ASU 2016-02, Leases In January 2016, FASB issued ASU 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities In November 2015, FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes In July 2015, FASB issued ASU 2015-11, Inventory (Topic 330) In August 2014, FASB issued ASU 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern In May 2014, FASB issued ASU 2014-09, Revenue from Contracts with Customers

Fair Value of Financial Instrum

Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2016
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	14. Fair Value of Financial Instruments—The carrying values of cash, receivables and accounts payable approximate their fair values because of the short maturity of these instruments. The fair value of the Company’s long-term debt and note payable to bank is estimated based on the quoted market prices for the same or similar issues or on the current rates offered to the Company for debt of the same remaining maturities. Such fair value approximates the respective carrying values of the Company’s long-term debt and note payable to bank.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income ("AOCI")	9 Months Ended
	Sep. 30, 2016
Text Block [Abstract]
Accumulated Other Comprehensive Income ("AOCI")	15. Accumulated Other Comprehensive Income (“AOCI”) — For the Nine Months Ended September 30, 2016 Balance, December 31, 2015 $ (3,541 ) Other comprehensive gain 85 Balance, March 31, 2016 $ (3,456 ) Other comprehensive loss (537 ) Balance, June 30, 2016 $ (3,993 ) Other comprehensive loss (436 ) Balance, September 30, 2016 $ (4,429 ) For the Nine Months Ended September 30, 2015 Balance, December 31, 2014 $ (1,970 ) Other comprehensive loss (248 ) Balance, March 31, 2015 $ (2,218 ) Other comprehensive loss (323 ) Balance, June 30, 2015 $ (2,541 ) Other comprehensive loss (897 ) Balance, September 30, 2015 $ (3,438 )

Equity Investment

Equity Investment	9 Months Ended
	Sep. 30, 2016
Equity Investment	16. The Company utilizes the equity method of accounting with respect to its investment in TyraTech Inc. (“TyraTech”), a Delaware corporation that specializes in developing, marketing and selling pesticide products containing natural oils. As of September 30, 2016, the Company’s ownership position in TyraTech was approximately 15.11%. As a result, our net income includes losses from this equity method investment, which represent our proportionate share of TyraTech’s estimated net losses for the current accounting period. For the three and nine months ended September 30, 2016, the Company recognized a loss of $180 and $309, respectively. For the three and nine months ended September 30, 2015, the Company recognized a loss of $389 and $580, respectively. At September 30, 2016, the carrying value of the Company’s investment in TyraTech was $2,228 and the quoted market value based on TyraTech’s share price (Level 1 input) was $1,450. At September 30, 2016, the Company performed an impairment review of its investment in TyraTech and concluded that the current condition was temporary and consequently determined that no impairment change was appropriate. TyraTech’s shares trade on the AIM market of the London Stock Exchange under the trading symbol ‘TYR’. The Company’s equity investment is included in Other Assets on the consolidated balance sheets. On August 2, 2016, the Company’s Netherlands-based subsidiary, AMVAC Netherlands BV, entered into a joint venture with China-based Huifeng Agrochemical Company, Ltd. The new entity, named Huifeng/AMVAC Innovation Co., Ltd., is based in Hong Kong and is intended to focus on activities such as market access and technology transfer between the two members. AMVAC Netherlands BV is a 50% owner of the new entity. The Company has concluded that it will account for the joint venture under the equity method. There has been no funding made to this joint venture as of September 30, 2016.
Biological Products For Agriculture
Equity Investment	17. In February 2016, the Company made an equity investment in Biological Products for Agriculture (“Bi-PA”) through its Netherlands wholly-owned subsidiary. Bi-PA develops biological plant protection products that can be used for the control of pests and disease of agricultural crops. As of September 30, 2016, the Company’s ownership position in Bi-PA was 15%. The Company utilizes the cost method of accounting with respect to this investment and will periodically review the investment for possible impairment. There was no impairment on the investment as of September 30, 2016. The investment is recorded within other assets on the condensed consolidated balance sheets.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2016
Income Tax Disclosure [Abstract]
Income Taxes	18. Income Taxes—For the three months ended September 30, 2016 and 2015, income tax expense was $1,409 and $1,643, respectively. For the nine months ended September 30, 2016 and 2015, income tax expense was $3,672 and $958, respectively and the effective tax rate was 27.9% in 2016 and 19.4% in 2015. These amounts are based upon management’s estimates for the full fiscal year, which are subject to review and revision. The Company’s Federal income tax returns for the years December 31, 2012 through December 31, 2014 are under examination by the Internal Revenue Service (“IRS”). The results of the audit are not determinable.

Subsequent Event

Subsequent Event	9 Months Ended
	Sep. 30, 2016
Subsequent Events [Abstract]
Subsequent Event	19. Subsequent Event— On October 11, 2016, the Company declared a $.01 per share cash dividend to stockholders as of October 28, 2016. The cash dividend is to be paid on November 11, 2016.

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	9 Months Ended
	Sep. 30, 2016
Property Plant And Equipment [Abstract]
Summary of Property, Plant and Equipment	Property, plant and equipment at September 30, 2016 and December 31, 2015 consists of the following: September 30, 2016 December 31, 2015 Land $ 2,458 $ 2,458 Buildings and improvements 15,067 14,726 Machinery and equipment 117,140 113,506 Office furniture, fixtures and equipment 4,857 4,997 Automotive equipment 383 491 Construction in progress 5,398 3,413 145,303 139,591 Less accumulated depreciation (97,543 ) (91,619 ) $ 47,760 $ 47,972

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2016
Inventory Disclosure [Abstract]
Components of Inventories	The components of inventories consist of the following: September 30, 2016 December 31, 2015 Finished products $ 123,311 $ 120,456 Raw materials 18,367 16,021 $ 141,678 $ 136,477

Segment Reporting (Tables)

Segment Reporting (Tables)	9 Months Ended
	Sep. 30, 2016
Segment Reporting [Abstract]
Summary of Business Sales Segmentation	Selective enterprise information is as follows: Three Months Ended September 30 Nine Months Ended September 30 2016 2015 2016 2015 Net sales: Insecticides $ 25,478 $ 23,539 $ 89,496 $ 85,484 Herbicides/soil fumigants/fungicides 34,242 32,682 80,009 71,973 Other, including plant growth regulators 13,328 7,420 23,148 23,497 Crop 73,048 63,641 192,653 180,954 Non-crop 9,399 8,845 31,992 24,620 Total net sales $ 82,447 $ 72,486 $ 224,645 $ 205,574 Net sales: US $ 60,033 $ 53,167 $ 161,661 $ 146,231 International 22,414 19,319 62,984 59,343 Total net sales $ 82,447 $ 72,486 $ 224,645 $ 205,574

Cash Dividend (Tables)

Cash Dividend (Tables)	9 Months Ended
	Sep. 30, 2016
Cash Dividends [Abstract]
Cash Dividend	The Company has declared and paid the following cash dividends in the period covered by this Form 10-Q: Declaration Date Record Date Distribution Date Dividend Per Share Total Paid June 13, 2016 June 30, 2016 July 12, 2016 $ 0.01 $ 289 March 16, 2015 April 3, 2015 April 17, 2015 $ 0.02 $ 572 December 11, 2014 December 26, 2014 January 9, 2015 $ 0.02 $ 569

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
	Sep. 30, 2016
Earnings Per Share [Abstract]
Components of Basic and Diluted Earnings Per Share	The components of basic and diluted earnings per share were as follows (in thousands): Three Months Ended September 30 Nine Months Ended September 30 2016 2015 2016 2015 Numerator: Net income attributable to AVD $ 2,877 $ 2,772 $ 8,917 $ 3,604 Denominator: Weighted average shares outstanding-basic 28,957 28,753 28,886 28,653 Dilutive effect of stock options and grants 539 536 499 555 29,496 29,289 29,385 29,208

Indebtedness (Tables)

Indebtedness (Tables)	9 Months Ended
	Sep. 30, 2016
Debt Disclosure [Abstract]
Summary of Short-Term and Long-Term Loan Balances in Condensed Consolidated Balance Sheets	The Company has a revolving line of credit and two other notes payable that together constitute the short-term and long-term loan balances shown in the condensed consolidated balance sheets at September 30, 2016 and December 31, 2015. During 2015 the Company adopted ASU 2015-03, Interest – Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs Indebtedness September 30, 2016 December 31, 2015 $000’s Long- term Short- term Total Long- term Short- term Total Revolving line of credit $ 45,000 $ — $ 45,000 $ 69,000 $ — $ 69,000 Deferred loan fees (512 ) — (512 ) (679 ) — (679 ) Notes payable — — — — 55 55 Total indebtedness $ 44,488 $ — $ 44,488 $ 68,321 $ 55 $ 68,376

Stock Based Compensation (Table

Stock Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2016
Stock Based Compensation, Unamortized Stock-Based Compensation and Remaining Weighted Average Period	The below tables illustrate the Company’s stock based compensation, unamortized stock-based compensation, and remaining weighted average period for the three months and nine months ended September 30, 2016 and 2015. Stock-Based Compensation for the Three months ended Stock-Based Compensation for the Nine months ended Unamortized Stock-Based Compensation Remaining Weighted Average Period (years) September 30, 2016 Incentive Stock Options $ 71 $ 252 $ 497 1.2 Restricted Stock 406 1,100 2,545 1.8 Performance Based Restricted Stock 100 240 857 1.4 Performance Based Options 11 64 173 1.2 Total $ 588 $ 1,656 $ 4,072 September 30, 2015 Incentive Stock Options $ 94 $ 325 $ 1,009 2.3 Restricted Stock 334 2,296 2,751 1.5 Performance Based Restricted Stock 18 222 686 1.8 Performance Based Options 12 100 373 2.2 Total $ 458 $ 2,943 $ 4,819
Summary of Option Activity	Option activity within each plan is as follows: Incentive Stock Option Plans Weighted Average Price Per Share Exercisable Weighted Average Price Per Share Balance outstanding, December 31, 2015 626,845 $ 9.25 $ 7.73 Options exercised (25,500 ) 7.50 Options forfeited (9,813 ) 11.49 Balance outstanding, March 31, 2016 591,532 $ 9.29 $ 7.84 Options exercised (12,900 ) 7.50 Options forfeited (5,000 ) 11.49 Balance outstanding, June 30, 2016 573,632 $ 9.31 $ 7.85 Options exercised (15,500 ) 7.50 Options forfeited (11,118 ) 11.49 Balance outstanding, September 30, 2016 547,014 $ 9.31 $ 7.87
Summary of Stock Options Summarized by Exercise Price	Information relating to stock options at September 30, 2016 summarized by exercise price is as follows: Outstanding Weighted Average Exercisable Weighted Average Exercise Price Per Share Shares Remaining Life (Months) Exercise Price Shares Exercise Price Incentive Stock Option Plan: $7.50 303,350 50 $ 7.50 303,350 $ 7.50 $11.32—$11.49 243,664 95 $ 11.57 25,507 $ 12.28 547,014 $ 9.31 328,857 $ 7.87
Weighted Average Exercise Prices for Options Granted and Exercisable and Weighted Average Remaining Contractual Life for Options Outstanding	The weighted average exercise prices for options granted and exercisable and the weighted average remaining contractual life for options outstanding as of September 30, 2016 was as follows: Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Months) Intrinsic Value (thousands) As of September 30, 2016: Incentive Stock Option Plans: Outstanding 547,014 $ 9.31 70 $ 3,690 Expected to Vest 540,064 $ 9.29 70 $ 3,658 Exercisable 328,857 $ 7.87 51 $ 2,693
Performance Based Stock Options
Summary of Option Activity	Performance based stock option activity is as follows: Incentive Stock Option Plans Weighted Average Price Per Share Exercisable Weighted Average Price Per Share Balance outstanding, December 31, 2015 98,410 $ 11.49 $ — Options forfeited (8,946 ) 11.49 Balance outstanding, March 31, 2016 89,464 $ 11.49 $ — Balance outstanding, June 30, 2016 89,464 $ 11.49 Options forfeited (7,130 ) 11.49 Balance outstanding, September 30, 2016 82,334 $ 11.49 $ —
Performance Incentive Stock Option
Summary of Stock Options Summarized by Exercise Price	Information relating to outstanding performance incentive stock options at September 30, 2016 summarized by exercise price is as follows: Outstanding Weighted Average Exercisable Weighted Average Exercise Price Per Share Shares Remaining Life (Months) Exercise Price Shares Exercise Price Performance Incentive Stock Option Plan: $11.49 82,334 15 $ 11.49 — $ — 82,334 $ 11.49 — $ —
Weighted Average Exercise Prices for Options Granted and Exercisable and Weighted Average Remaining Contractual Life for Options Outstanding	The weighted average exercise prices for options granted and exercisable and the weighted average remaining contractual life for options outstanding as of September 30, 2016 are as follows: Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Months) Intrinsic Value (thousands) As of September 30, 2016: Incentive Stock Option Plans: Outstanding 82,334 $ 11.49 15 $ 376 Expected to Vest 73,632 $ 11.49 15 $ 336 Exercisable — $ — — $ —
Restricted Stock
Summary of Non-Vested Shares	Restricted Shares — Nine Months Ended September 30, 2016 Nine Months Ended September 30, 2015 Number of Shares Weighted Average Grant Date Fair Value Number of Shares Weighted Average Grant Date Fair Value Nonvested shares at January 1 st 362,841 $ 20.43 560,842 $ 21.44 Granted — — 30,000 11.42 Vested (127,274 ) 31.29 (192,266 ) 20.47 Forfeited (16,008 ) 23.67 (422 ) 14.92 Nonvested shares at March 31 st 219,559 $ 14.59 398,154 $ 21.17 Granted 140,541 15.08 21,005 14.28 Vested (22,639 ) 15.63 (28,505 ) 13.53 Forfeited (6,457 ) 14.98 (1,201 ) 14.92 Nonvested shares at June 30 th 331,004 $ 14.72 389,453 $ 21.37 Granted 1,668 16.75 13,196 12.88 Vested (2,566 ) 19.18 (19,000 ) 27.93 Forfeited (12,822 ) 14.98 (26,723 ) 22.64 Nonvested shares at September 30 th 317,284 $ 14.69 356,926 $ 20.62
Performance Based Restricted Shares
Summary of Non-Vested Shares	Performance Based Restricted Shares — Nine Months Ended September 30, 2016 Nine Months Ended September 30, 2015 Number of Shares Weighted Average Grant Date Fair Value Number of Shares Weighted Average Grant Date Fair Value Nonvested shares at January 1 st 104,403 $ 17.05 103,907 $ 17.77 Granted — — 7,500 10.96 Forfeited (9,395 ) 17.65 — — Nonvested shares at March 31 st 95,008 $ 16.99 111,407 $ 17.31 Granted 52,170 14.39 — — Forfeited (19,612 ) 28.25 — — Nonvested shares at June 30 th 127,566 $ 14.20 111,407 $ 17.31 Granted — — 3,196 12.37 Forfeited (8,544 ) 14.39 (10,200 ) 18.43 Nonvested shares at September 30 th 119,022 $ 14.18 104,403 $ 17.05

Accumulated Other Comprehensi34

Accumulated Other Comprehensive Income ("AOCI") (Tables)	9 Months Ended
	Sep. 30, 2016
Text Block [Abstract]
Beginning Balance, Annual Activity and Ending Balance of Accumulated Other Comprehensive Loss of Foreign Currency Translation Adjustments	The following table lists the beginning balance, annual activity and ending balance of accumulated other comprehensive loss, which consists of foreign currency translation adjustments: For the Nine Months Ended September 30, 2016 Balance, December 31, 2015 $ (3,541 ) Other comprehensive gain 85 Balance, March 31, 2016 $ (3,456 ) Other comprehensive loss (537 ) Balance, June 30, 2016 $ (3,993 ) Other comprehensive loss (436 ) Balance, September 30, 2016 $ (4,429 ) For the Nine Months Ended September 30, 2015 Balance, December 31, 2014 $ (1,970 ) Other comprehensive loss (248 ) Balance, March 31, 2015 $ (2,218 ) Other comprehensive loss (323 ) Balance, June 30, 2015 $ (2,541 ) Other comprehensive loss (897 ) Balance, September 30, 2015 $ (3,438 )

Summary of Property, Plant and

Summary of Property, Plant and Equipment (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Property, plant and equipment, Gross	$ 145,303	$ 139,591
Less accumulated depreciation	(97,543)	(91,619)
Total Property, plant and equipment	47,760	47,972
Land
Property, Plant and Equipment [Line Items]
Property, plant and equipment, Gross	2,458	2,458
Buildings and improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, Gross	15,067	14,726
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, Gross	117,140	113,506
Office furniture, fixtures and equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, Gross	4,857	4,997
Automotive equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, Gross	383	491
Construction in progress
Property, Plant and Equipment [Line Items]
Property, plant and equipment, Gross	$ 5,398	$ 3,413

Property, Plant And Equipment -

Property, Plant And Equipment - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Property Plant And Equipment [Abstract]
Depreciation expense related to property, plant and equipment	$ 2,021	$ 2,231	$ 6,334	$ 6,762
Elimination of Assets and Accumulated depreciation			$ 410	$ 388

Components of Inventories (Deta

Components of Inventories (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Inventory Disclosure [Abstract]
Finished products	$ 123,311	$ 120,456
Raw materials	18,367	16,021
Total Inventories	$ 141,678	$ 136,477

Segment Reporting - Additional

Segment Reporting - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2016Segment
Segment Reporting [Abstract]
Number of reportable business segments	1

Summary of Business Sales Segme

Summary of Business Sales Segmentation as per Product (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Net sales:
Crop	$ 73,048	$ 63,641	$ 192,653	$ 180,954
Non-crop	9,399	8,845	31,992	24,620
Total net sales	82,447	72,486	224,645	205,574
Insecticides
Net sales:
Crop	25,478	23,539	89,496	85,484
Herbicides/Soil Fumigants/Fungicides
Net sales:
Crop	34,242	32,682	80,009	71,973
Other, Including Plant Growth Regulators
Net sales:
Crop	$ 13,328	$ 7,420	$ 23,148	$ 23,497

Summary of Business Sales Seg40

Summary of Business Sales Segmentation as per Location (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Net sales:
Total net sales	$ 82,447	$ 72,486	$ 224,645	$ 205,574
US
Net sales:
Total net sales	60,033	53,167	161,661	146,231
International
Net sales:
Total net sales	$ 22,414	$ 19,319	$ 62,984	$ 59,343

Cash Dividend (Detail)

Cash Dividend (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2015	Mar. 31, 2015	Sep. 30, 2016
Supplemental Cash Flow Elements [Abstract]
Cash dividend declaration date	Mar. 16, 2015	Dec. 11, 2014	Jun. 13, 2016
Cash dividend record date	Apr. 3, 2015	Dec. 26, 2014	Jun. 30, 2016
Cash dividend distributed date	Apr. 17, 2015	Jan. 9, 2015	Jul. 12, 2016
Cash dividend per share	$ 0.02	$ 0.02	$ 0.01
Cash dividend paid	$ 572	$ 569	$ 289

Components of Basic and Diluted

Components of Basic and Diluted Earnings Per Share (Detail) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Numerator:
Net income attributable to AVD	$ 2,877	$ 2,772	$ 8,917	$ 3,604
Denominator:
Weighted average shares outstanding-basic	28,957	28,753	28,886	28,653
Dilutive effect of stock options and grants	539	536	499	555
Weighted average shares outstanding-assuming dilution	29,496	29,289	29,385	29,208

Earnings Per Share - Additional

Earnings Per Share - Additional Information (Detail) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Earnings Per Share [Abstract]
Stock options excluded from computation of diluted earning per share	0	0	0	0

Summary Revolving Line of Credi

Summary Revolving Line of Credit And Various Notes Payable Constitute Short-Term and Long-Term Loan Balances Together (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Debt Disclosure [Abstract]
Revolving line of credit, Long Term	$ 45,000	$ 69,000
Revolving line of credit, Short-term	0	0
Revolving line of credit	45,000	69,000
Deferred loan fees, Long Term	(512)	(679)
Deferred loan fees, Short-term	0	0
Deferred loan fees	(512)	(679)
Notes payable, Long Term	0	0
Notes payable, Short-term	0	55
Notes payable	0	55
Long-term debt and other notes payable, excluding current installments	44,488	68,321
Current installments of other notes payable	0	55
Total indebtedness	$ 44,488	$ 68,376

Indebtedness - Additional Infor

Indebtedness - Additional Information (Detail) - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Apr. 14, 2015
Debt Instrument [Line Items]
Available borrowings capacity under credit agreement		$ 40,189,000
Senior secured credit facility term	5 years
Senior secured credit facility, maturity date	Jun. 17, 2018
Description of variable rate basis	(i) LIBOR plus the “Applicable Rate” which is based upon the Consolidated Funded Debt Ratio (“Eurocurrency Rate Loan”) or (ii) the greater of (x) the Prime Rate, (y) the Federal Funds Rate plus 0.5%, and (z) the Daily One-Month LIBOR Rate plus 1.00%, plus, in the case of (x), (y) or (z) the Applicable Rate (“Alternate Base Rate Loan”).
Ratio of consolidated current assets to consolidated current liabilities			120.00%
Revolving Line of Credit
Debt Instrument [Line Items]
Available borrowings capacity under credit agreement	$ 200,000,000
Maximum
Debt Instrument [Line Items]
Consolidated funded debt ratio			350.00%
Capacity to increase borrowings under credit agreement	95,985,000
Minimum
Debt Instrument [Line Items]
Consolidated funded debt ratio			325.00%
Term Loan | Maximum
Debt Instrument [Line Items]
Accordion feature	$ 100,000,000
Federal Funds Rate
Debt Instrument [Line Items]
Basis spread on variable rate	0.50%
LIBOR Rate
Debt Instrument [Line Items]
Basis spread on variable rate	1.00%

Unamortized Stock-Based Compens

Unamortized Stock-Based Compensation Expenses (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	$ 588	$ 458	$ 1,656	$ 2,943
Unamortized Stock-Based Compensation	4,072	4,819	4,072	4,819
Incentive Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	71	94	$ 252	$ 325
Remaining Weighted Average Period (years)			1 year 2 months 12 days	2 years 3 months 18 days
Unamortized Stock-Based Compensation related to stock options	497	1,009	$ 497	$ 1,009
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	406	334	$ 1,100	$ 2,296
Remaining Weighted Average Period (years)			1 year 9 months 18 days	1 year 6 months
Unamortized Stock-Based Compensation other than options	2,545	2,751	$ 2,545	$ 2,751
Performance Based Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	100	18	$ 240	$ 222
Remaining Weighted Average Period (years)			1 year 4 months 24 days	1 year 9 months 18 days
Unamortized Stock-Based Compensation other than options	857	686	$ 857	$ 686
Performance Based Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	11	12	$ 64	$ 100
Remaining Weighted Average Period (years)			1 year 2 months 12 days	2 years 2 months 12 days
Unamortized Stock-Based Compensation related to stock options	$ 173	$ 373	$ 173	$ 373

Stock Based Compensation - Addi

Stock Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Sep. 30, 2016	Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employees options granted							0
Stock-based compensation	$ 588			$ 458			$ 1,656	$ 2,943
Performance Incentive Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	11			12			64	100
Nonvested unamortized stock-based compensation expense, value	173						$ 173
Nonvested unamortized stock-based compensation expense, contractual term							1 year 2 months 12 days
Incentive Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	71			94			$ 252	325
Nonvested unamortized stock-based compensation expense, value	497			1,009			$ 497	$ 1,009
Nonvested unamortized stock-based compensation expense, contractual term							1 year 2 months 12 days	2 years 3 months 18 days
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	$ 406			$ 334			$ 1,100	$ 2,296
Nonvested unamortized stock-based compensation expense, contractual term							1 year 9 months 18 days	1 year 6 months
Number of shares granted to employees	1,668	140,541		13,196	21,005	30,000	142,209	64,201
Number of Shares, Vested	2,566	22,639	127,274	19,000	28,505	192,266
Number of years of service before cliff vesting							3 years	3 years
Weighted Average Grant-Date Fair Value, Granted	$ 16.75	$ 15.08		$ 12.88	$ 14.28	$ 11.42	$ 15.10	$ 12.66
Unamortized Stock-Based Compensation other than options	$ 2,545			$ 2,751			$ 2,545	$ 2,751
Restricted Stock | Vested immediately
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Vested							21,139	21,005
Restricted Stock | Vest after three years
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Vested							121,070	3,196
Restricted Stock | Vest after 90 days
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Vested								7,500
Performance Based Restricted Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	100			$ 18			$ 240	$ 222
Nonvested unamortized stock-based compensation expense, contractual term							1 year 4 months 24 days
Number of shares granted to employees		52,170		3,196		7,500	52,170	10,696
Weighted Average Grant-Date Fair Value, Granted		$ 14.39		$ 12.37		$ 10.96
Unamortized Stock-Based Compensation other than options	$ 857						$ 857
Targeted performance percentage	200.00%			200.00%			200.00%	200.00%
Performance Based Restricted Shares | Vested on January 6, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Vested								7,500
Cliff vesting date							Jan. 6, 2019	Jan. 5, 2018
Performance Based Restricted Shares | Performance Based Shares Based Upon Financial Performance of Earnings before Interest Tax ("EBIT") and Net Sales Goal for the Period Commencing July 1, 2015 and Ending June 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of shares vesting based on Performance							80.00%
Earnings before income tax goal weight, percentage							50.00%
Net sales goal weight, percentage							30.00%
Performance Based Restricted Shares | Performance Based Shares Based Upon AVD Stock Price Appreciation Over the Course of the Period Commencing July 1, 2015, Ending June 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of shares vesting based on Performance							20.00%
Earnings before income tax goal weight, percentage								20.00%
Performance Based Restricted Shares | Vested on August 1, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Vested								3,196
Cliff vesting date								Aug. 1, 2018
Performance Based Restricted Shares | Performance Based Shares Based Upon Financial Performance of Earnings before Interest Tax ("EBIT") and Net Sales Goal for the Period Commencing January 1, 2016 and Ending June 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of shares vesting based on Performance								80.00%
Earnings before income tax goal weight, percentage								50.00%
Net sales goal weight, percentage								30.00%
Performance Based Restricted Shares | Performance Based Shares Related to Net Income Weighted at 50%, Net Sales Weighted at 30%, Commencing July 1, 2015 and Ending June 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Grant-Date Fair Value, Granted							$ 15.08
Performance Based Restricted Shares | Remaining 20% of Performance Based Shares are Based Upon AVD Stock Price Appreciation for the Period Commencing July 1, 2015 and Ending June 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Grant-Date Fair Value, Granted							$ 11.63

Summary of Option Activity (Det

Summary of Option Activity (Detail) - $ / shares	3 Months Ended
	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incentive Stock Option Plans, Beginning balance	573,632	591,532	626,845
Incentive Stock Option Plans, Option exercised	(15,500)	(12,900)	(25,500)
Incentive Stock Option Plans, Option forfeited	(11,118)	(5,000)	(9,813)
Incentive Stock Option Plans, Ending balance	547,014	573,632	591,532
Weighted Average Price Per Share, Beginning balance	$ 9.31	$ 9.29	$ 9.25
Weighted Average Price Per Share, Option exercised	7.50	7.50	7.50
Weighted Average Price Per Share, Option forfeited	11.49	11.49	11.49
Weighted Average Price Per Share, Ending balance	9.31	9.31	9.29
Exercisable Weighted Average Price Per Share, Beginning balance	7.85	7.84	7.73
Exercisable Weighted Average Price Per Share, Ending balance	$ 7.87	$ 7.85	$ 7.84
Performance Based Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incentive Stock Option Plans, Beginning balance	89,464	89,464	98,410
Incentive Stock Option Plans, Option forfeited	(7,130)		(8,946)
Incentive Stock Option Plans, Ending balance	82,334	89,464	89,464
Weighted Average Price Per Share, Beginning balance	$ 11.49	$ 11.49	$ 11.49
Weighted Average Price Per Share, Option forfeited	11.49		11.49
Weighted Average Price Per Share, Ending balance	$ 11.49	$ 11.49	$ 11.49

Summary of Stock Options Summar

Summary of Stock Options Summarized by Exercise Price (Detail) - $ / shares	9 Months Ended
	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Weighted Average, Exercise Price	$ 9.31	$ 9.31	$ 9.29	$ 9.25
Exercisable Weighted Average, Exercise Price	$ 7.87	$ 7.85	$ 7.84	$ 7.73
Incentive Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Weighted Average, Shares	547,014
Outstanding Weighted Average, Remaining Life (Months)	70 months
Outstanding Weighted Average, Exercise Price	$ 9.31
Exercisable Weighted Average, Shares	328,857
Exercisable Weighted Average, Exercise Price	$ 7.87
Incentive Stock Option Plan | Range One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Per Share, Lower Range	$ 7.50
Outstanding Weighted Average, Shares	303,350
Outstanding Weighted Average, Remaining Life (Months)	50 months
Outstanding Weighted Average, Exercise Price	$ 7.50
Exercisable Weighted Average, Shares	303,350
Exercisable Weighted Average, Exercise Price	$ 7.50
Incentive Stock Option Plan | Range Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Per Share, Lower Range	11.32
Exercise Price Per Share, Upper Range	$ 11.49
Outstanding Weighted Average, Shares	243,664
Outstanding Weighted Average, Remaining Life (Months)	95 months
Outstanding Weighted Average, Exercise Price	$ 11.57
Exercisable Weighted Average, Shares	25,507
Exercisable Weighted Average, Exercise Price	$ 12.28
Performance Incentive Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Weighted Average, Remaining Life (Months)	15 months
Outstanding Weighted Average, Exercise Price	$ 11.49
Outstanding Weighted Average, Shares	82,334
Performance Incentive Stock Option | Range Three
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Weighted Average, Remaining Life (Months)	15 months
Outstanding Weighted Average, Exercise Price	$ 11.49
Outstanding Weighted Average, Shares	82,334

Weighted Average Exercise Price

Weighted Average Exercise Prices for Options Granted and Exercisable and Weighted Average Remaining Contractual Life for Options Outstanding (Detail) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding	547,014	573,632	591,532	626,845
Weighted Average Exercise Price, Outstanding	$ 9.31	$ 9.31	$ 9.29	$ 9.25
Weighted Average Exercisable, Exercise Price	$ 7.87	$ 7.85	$ 7.84	$ 7.73
Incentive Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding	547,014
Number of Shares, Expected to Vest	540,064
Number of Shares, Exercisable	328,857
Weighted Average Exercise Price, Outstanding	$ 9.31
Weighted Average Exercise Price, Expected to Vest	9.29
Weighted Average Exercisable, Exercise Price	$ 7.87
Weighted Average Remaining Life, Outstanding	70 months
Weighted Average Remaining Contractual Life, Expected to Vest	70 months
Weighted Average Remaining Contractual Life, Exercisable	51 months
Intrinsic Value, Outstanding	$ 3,690
Intrinsic Value, Expected to Vest	3,658
Intrinsic Value, Exercisable	$ 2,693
Performance Incentive Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding	82,334
Number of Shares, Expected to Vest	73,632
Weighted Average Exercise Price, Outstanding	$ 11.49
Weighted Average Exercise Price, Expected to Vest	$ 11.49
Weighted Average Remaining Life, Outstanding	15 months
Weighted Average Remaining Contractual Life, Expected to Vest	15 months
Intrinsic Value, Outstanding	$ 376
Intrinsic Value, Expected to Vest	$ 336

Summary of Non-Vested Shares (D

Summary of Non-Vested Shares (Detail) - Restricted Stock - $ / shares	3 Months Ended						9 Months Ended
	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Sep. 30, 2016	Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Beginning balance	331,004	219,559	362,841	389,453	398,154	560,842	362,841	560,842
Number of Shares, Granted	1,668	140,541		13,196	21,005	30,000	142,209	64,201
Number of Shares, Vested	(2,566)	(22,639)	(127,274)	(19,000)	(28,505)	(192,266)
Number of Shares, Forfeited	(12,822)	(6,457)	(16,008)	(26,723)	(1,201)	(422)
Number of Shares, Ending Balance	317,284	331,004	219,559	356,926	389,453	398,154	317,284	356,926
Weighted Average Grant-Date Fair Value, Beginning balance	$ 14.72	$ 14.59	$ 20.43	$ 21.37	$ 21.17	$ 21.44	$ 20.43	$ 21.44
Weighted Average Grant-Date Fair Value, Granted	16.75	15.08		12.88	14.28	11.42	15.10	12.66
Weighted Average Grant-Date Fair Value, Vested	19.18	15.63	31.29	27.93	13.53	20.47
Weighted Average Grant-Date Fair Value, Forfeited	14.98	14.98	23.67	22.64	14.92	14.92
Weighted Average Grant-Date Fair Value, Ending balance	$ 14.69	$ 14.72	$ 14.59	$ 20.62	$ 21.37	$ 21.17	$ 14.69	$ 20.62

Status Summary of Non-Vested Sh

Status Summary of Non-Vested Shares (Detail) - Performance Based Restricted Shares - $ / shares	3 Months Ended						9 Months Ended
	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Sep. 30, 2016	Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Beginning balance	127,566	95,008	104,403	111,407	111,407	103,907	104,403	103,907
Number of Shares, Granted		52,170		3,196		7,500	52,170	10,696
Number of Shares, Forfeited	(8,544)	(19,612)	(9,395)	(10,200)
Number of Shares, Ending Balance	119,022	127,566	95,008	104,403	111,407	111,407	119,022	104,403
Weighted Average Grant-Date Fair Value, Beginning balance	$ 14.20	$ 16.99	$ 17.05	$ 17.31	$ 17.31	$ 17.77	$ 17.05	$ 17.77
Weighted Average Grant-Date Fair Value, Granted		14.39		12.37		10.96
Weighted Average Grant-Date Fair Value, Forfeited	14.39	28.25	17.65	18.43
Weighted Average Grant-Date Fair Value, Ending balance	$ 14.18	$ 14.20	$ 16.99	$ 17.05	$ 17.31	$ 17.31	$ 14.18	$ 17.05

Litigation and Environmental -

Litigation and Environmental - Additional Information (Detail)	Aug. 21, 2012PersonCase	Sep. 30, 2016a
Delaware
Loss Contingencies [Line Items]
Number of claimants | Person	235
Number of consolidated cases | Case	1
DeChene Farms Matter
Loss Contingencies [Line Items]
Number of acres | a		300

Beginning Balance, Annual Activ

Beginning Balance, Annual Activity and Ending Balance of Accumulated Other Comprehensive Income Loss (Detail) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Sep. 30, 2016	Sep. 30, 2015
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	$ 274,834	$ 271,534	$ 268,326				$ 268,326
Other comprehensive gain (loss)	(436)	(537)	85	$ (897)			(888)	$ (1,468)
Balance	278,261	274,834	271,534				278,261
Accumulated Other Comprehensive Income (Loss)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(3,993)	(3,456)	(3,541)	(2,541)	$ (2,218)	$ (1,970)	(3,541)	(1,970)
Other comprehensive gain (loss)	(436)	(537)	85	(897)	(323)	(248)
Balance	$ (4,429)	$ (3,993)	$ (3,456)	$ (3,438)	$ (2,541)	$ (2,218)	$ (4,429)	$ (3,438)

Equity Method Investment - Addi

Equity Method Investment - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Aug. 02, 2016
Equity Method Investments [Line Items]
Gain loss from equity method investment			$ (309)	$ (580)
TyraTech Inc.
Equity Method Investments [Line Items]
Equity investment ownership position	15.11%		15.11%
Gain loss from equity method investment	$ (180)	$ (389)	$ (309)	$ (580)
Carrying value of equity investment	2,228		2,228
Quoted market value of equity investment	$ 1,450		$ 1,450
Huifeng/AMVAC Innovation Co., Ltd.
Equity Method Investments [Line Items]
Equity investment ownership position					50.00%

Equity Investment - Additional

Equity Investment - Additional Information (Detail) - Bi-PA	9 Months Ended
	Sep. 30, 2016USD ($)
Schedule of Cost-method Investments [Line Items]
Cost method ownership percentage	15.00%
Cost-method Investments, Impairment	$ 0

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Income Tax Disclosure [Abstract]
Income tax expense	$ 1,409	$ 1,643	$ 3,672	$ 958
Effective tax rate			27.90%	19.40%

Subsequent Event - Additional I

Subsequent Event - Additional Information (Detail) - $ / shares	Oct. 11, 2016	Jun. 30, 2016	Jun. 30, 2015	Mar. 31, 2015	Sep. 30, 2016
Subsequent Event [Line Items]
Cash dividends on common stock, per share		$ 0.01
Cash dividend declaration date			Mar. 16, 2015	Dec. 11, 2014	Jun. 13, 2016
Cash dividend record date			Apr. 3, 2015	Dec. 26, 2014	Jun. 30, 2016
Cash dividend distributed date			Apr. 17, 2015	Jan. 9, 2015	Jul. 12, 2016
Subsequent Event
Subsequent Event [Line Items]
Cash dividends on common stock, per share	$ 0.01
Cash dividend declaration date	Oct. 11, 2016
Cash dividend record date	Oct. 28, 2016
Cash dividend distributed date	Nov. 11, 2016